| Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer L Xue, X Rovira, P Scholler, H Zhao, J Liu, JP Pin, P Rondard Nature chemical biology 11 (2), 134-140, 2015 | 196 | 2015 |
| Structural basis of the activation of a metabotropic GABA receptor H Shaye, A Ishchenko, JH Lam, GW Han, L Xue, P Rondard, JP Pin, ... Nature 584 (7820), 298-303, 2020 | 105 | 2020 |
| Rearrangement of the transmembrane domain interfaces associated with the activation of a GPCR hetero-oligomer L Xue, Q Sun, H Zhao, X Rovira, S Gai, Q He, JP Pin, J Liu, P Rondard Nature communications 10 (1), 2765, 2019 | 54 | 2019 |
| A novel mutation in the transmembrane 6 domain of GABBR2 leads to a Rett-like phenotype ML Vuillaume, M Jeanne, L Xue, S Blesson, AS Denommé-Pichon, ... Annals of Neurology 83 (2), 437-439, 2018 | 24 | 2018 |
| The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment YT Liu, F Liu, L Cao, L Xue, WT Gu, YZ Zheng, H Tang, Y Wang, H Yao, ... Acta neuropathologica 140, 377-396, 2020 | 22 | 2020 |
| Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface L Liu, Z Fan, X Rovira, L Xue, S Roux, I Brabet, M Xin, JP Pin, P Rondard, ... Elife 10, e70188, 2021 | 20 | 2021 |
| Tumor-associated macrophages: new horizons for pituitary adenoma researches C Han, S Lin, X Lu, L Xue, ZB Wu Frontiers in endocrinology 12, 785050, 2021 | 14 | 2021 |
| TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT H Yao, W Xie, Y Dai, Y Liu, W Gu, J Li, L Wu, J Xie, W Rui, B Ren, L Xue, ... Neuro-oncology 24 (8), 1286-1297, 2022 | 10 | 2022 |
| Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors XB Wang, TY Han, JG Ma, C He, L Xue, X Zhang, ZB Wu Frontiers in Endocrinology 13, 1056327, 2022 | 4 | 2022 |
| Structural basis for distinct quality control mechanisms of GABAB receptor during evolution S Zhang, L Xue, X Liu, XC Zhang, R Zhou, H Zhao, C Shen, JP Pin, ... The FASEB Journal 34 (12), 16348-16363, 2020 | 4 | 2020 |
| Phosphorylation-independent desensitization of metabotropic glutamate receptor 5 by G protein-coupled receptor kinase 2 in HEK 293 cells Z Zhang, L Xue, H Guo, Y Li, H Ding, S Huang Molecular Biology 47, 123-130, 2013 | 4 | 2013 |
| DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study H Tang, Y Cheng, X Lou, H Yao, J Xie, W Gu, X Huang, Y Liu, S Lin, Y Dai, ... Endocrine 80 (2), 419-424, 2023 | 2 | 2023 |
| Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis N Huang, Y Feng, Y Liu, Y Zhang, L Liu, B Zhang, T Zhang, Z Su, L Xue, ... International Immunopharmacology 134, 112159, 2024 | | 2024 |
| Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage–tumor interaction axes among different lineages of pituitary neuroendocrine tumors S Lin, Y Dai, C Han, T Han, L Zhao, R Wu, J Liu, B Zhang, N Huang, Y Liu, ... Genome Medicine 16 (1), 60, 2024 | | 2024 |
| Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors Y Cheng, Y Dai, H Tang, X Lu, J Xie, W Xie, Q Zhang, Y Liu, S Lin, H Yao, ... Acta Neuropathologica Communications 12 (1), 61, 2024 | | 2024 |
| Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas Y Cheng, D Wang, H Tang, D Tong, W Zhao, S Lin, H Yao, W Lv, X Zhang, ... Cancers 16 (4), 726, 2024 | | 2024 |
| Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors L Wang, C Wei, Y Wang, N Huang, T Zhang, Y Dai, L Xue, S Lin, ZB Wu Frontiers in Endocrinology 14, 1149997, 2023 | | 2023 |
